Opus Genetics (IRD) Stock Price

Opus Genetics Price

NASDAQ·CLOSED
3.84USD+0.46 (+12.89 %)
Market closed

Revenue has compounded at 31.3% per year over the past 19 years to 14.20 M USD. Opus Genetics's net margin stands at -349.3%, up from -9,625.3% several years earlier. Analysts set a median price target of 8.16 USD, implying 112.5% above the current price. Of 15 analysts, 14 rate the stock a buy — an overall Buy consensus. The stock trades about 262% above its 52-week low.

Opus Genetics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Opus Genetics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Opus Genetics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Opus Genetics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Opus Genetics Stock Price History
DateOpus Genetics Price
7/30/20263.84 USD
7/29/20263.38 USD
7/27/20263.28 USD
7/23/20262.92 USD
7/22/20263.05 USD
7/21/20263.06 USD
7/20/20263.05 USD
7/17/20263.27 USD
7/16/20263.28 USD
7/15/20263.48 USD
7/14/20263.56 USD
7/13/20263.81 USD
7/10/20263.92 USD
7/9/20264.02 USD
7/8/20264.01 USD
7/7/20264.05 USD
7/6/20264.24 USD
7/2/20264.23 USD
7/1/20264.18 USD
6/30/20264.11 USD
6/29/20264.06 USD
6/26/20264.00 USD
6/25/20263.72 USD
6/24/20263.71 USD
6/23/20264.08 USD
6/22/20264.05 USD
6/18/20264.07 USD
6/17/20264.06 USD
6/16/20263.90 USD
6/15/20263.91 USD
6/12/20264.04 USD
6/11/20263.91 USD
6/10/20264.07 USD
6/9/20264.08 USD
6/8/20264.03 USD
6/5/20264.03 USD
6/4/20264.64 USD
6/3/20264.20 USD
6/2/20263.99 USD
6/1/20264.12 USD
5/29/20264.36 USD
5/28/20264.20 USD
5/27/20264.14 USD
5/26/20264.09 USD
5/22/20264.26 USD
5/21/20264.29 USD
5/20/20264.44 USD
5/19/20264.26 USD
5/18/20264.44 USD
5/15/20264.80 USD
5/14/20264.93 USD
5/13/20265.03 USD
5/12/20265.18 USD
5/11/20265.12 USD
5/8/20264.99 USD
5/7/20265.36 USD
5/6/20265.26 USD
5/5/20265.20 USD
5/4/20265.22 USD
5/1/20265.14 USD
4/30/20265.11 USD
4/29/20264.67 USD
4/28/20265.00 USD
4/27/20265.12 USD
4/24/20265.23 USD
4/23/20265.28 USD
4/22/20265.47 USD
4/21/20265.34 USD
4/20/20265.54 USD
4/17/20265.75 USD
4/16/20265.75 USD
4/15/20265.71 USD
4/14/20265.55 USD
4/13/20265.57 USD
4/10/20265.36 USD
4/9/20265.50 USD
4/8/20265.15 USD
4/7/20264.92 USD
4/6/20264.61 USD
4/2/20264.55 USD
4/1/20264.69 USD
3/31/20264.55 USD
3/30/20264.35 USD
3/27/20264.35 USD
3/26/20264.52 USD
3/25/20264.75 USD
3/24/20264.51 USD
3/23/20264.59 USD
3/20/20264.39 USD
3/19/20264.58 USD
3/18/20264.66 USD
3/17/20264.80 USD
3/16/20265.19 USD
3/13/20265.03 USD
3/12/20264.84 USD
3/11/20265.01 USD
3/10/20264.85 USD
3/9/20264.77 USD
3/6/20264.89 USD
3/5/20264.77 USD
3/4/20264.57 USD
3/3/20264.25 USD
3/2/20264.33 USD
2/27/20264.16 USD
2/26/20263.59 USD
2/25/20263.50 USD
2/24/20263.64 USD
2/23/20263.45 USD
2/20/20263.39 USD
2/19/20263.57 USD
2/18/20263.75 USD
2/17/20263.89 USD
2/13/20263.64 USD
2/12/20263.39 USD
2/11/20263.29 USD
2/10/20263.49 USD
2/9/20263.38 USD
2/6/20263.01 USD
2/5/20262.58 USD
2/4/20262.29 USD
2/3/20262.40 USD
2/2/20262.32 USD
1/30/20262.31 USD
1/29/20262.50 USD
1/28/20262.70 USD
1/27/20262.83 USD
1/26/20262.81 USD
1/23/20262.56 USD
1/22/20262.50 USD
1/21/20262.36 USD
1/20/20262.26 USD
1/16/20262.10 USD
1/15/20262.08 USD
1/14/20262.17 USD
1/13/20262.14 USD
1/12/20262.05 USD
1/9/20261.93 USD
1/8/20262.00 USD
1/7/20262.11 USD
1/6/20262.08 USD
1/5/20262.13 USD
1/2/20262.12 USD
12/31/20252.01 USD
12/30/20251.95 USD
12/29/20251.99 USD
12/26/20252.02 USD
12/24/20252.04 USD
12/23/20252.01 USD
12/22/20252.06 USD
12/19/20252.00 USD
12/18/20251.98 USD
12/17/20252.02 USD
12/16/20252.14 USD
12/15/20252.13 USD
12/12/20252.36 USD
12/11/20252.44 USD
12/10/20252.50 USD
12/9/20252.39 USD
12/8/20252.29 USD
12/5/20252.27 USD
12/4/20252.23 USD
12/3/20252.09 USD
12/2/20251.99 USD
12/1/20252.00 USD
11/28/20252.13 USD
11/26/20252.02 USD
11/25/20251.98 USD
11/24/20252.00 USD
11/21/20251.91 USD
11/20/20251.93 USD
11/19/20251.86 USD
11/18/20251.88 USD
11/17/20251.74 USD
11/14/20251.88 USD
11/13/20251.85 USD
11/12/20251.92 USD
11/11/20251.97 USD
11/10/20251.97 USD
11/7/20252.00 USD
11/6/20252.03 USD
11/5/20252.12 USD
11/4/20252.17 USD
11/3/20252.14 USD
10/31/20252.30 USD
10/30/20251.97 USD
10/29/20251.98 USD
10/28/20251.93 USD
10/27/20252.00 USD
10/24/20251.99 USD
10/23/20252.00 USD
10/22/20251.95 USD
10/21/20252.01 USD
10/20/20251.98 USD
10/17/20251.87 USD
10/16/20252.01 USD
10/15/20252.00 USD
10/14/20252.00 USD
10/13/20252.00 USD
10/10/20251.96 USD
10/9/20251.99 USD
10/8/20252.05 USD
10/7/20252.03 USD
10/6/20252.02 USD
10/3/20251.88 USD
10/2/20251.80 USD
10/1/20251.80 USD
9/30/20251.65 USD
9/29/20251.79 USD
9/26/20251.82 USD
9/25/20251.72 USD
9/24/20251.64 USD
9/23/20251.66 USD
9/22/20251.71 USD
9/19/20251.52 USD
9/18/20251.49 USD
9/17/20251.43 USD
9/16/20251.40 USD
9/15/20251.37 USD
9/12/20251.38 USD
9/11/20251.41 USD
9/10/20251.33 USD
9/9/20251.36 USD
9/8/20251.40 USD
9/5/20251.27 USD
9/4/20251.28 USD
9/3/20251.28 USD
9/2/20251.23 USD
8/29/20251.22 USD
8/28/20251.19 USD
8/27/20251.20 USD
8/26/20251.21 USD
8/25/20251.15 USD
8/22/20251.15 USD
8/21/20251.15 USD
8/20/20251.16 USD
8/19/20251.11 USD
8/18/20251.15 USD
8/15/20251.20 USD
8/14/20251.18 USD
8/13/20251.10 USD
8/12/20251.11 USD
8/11/20251.06 USD
8/8/20251.07 USD
8/7/20251.09 USD
8/6/20251.10 USD
8/5/20251.11 USD
8/4/20251.08 USD
8/1/20251.07 USD
Access this data via the Eulerpool API
Get Free API Key

Opus Genetics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
19.05 M USD
-9.97 M USD
-9.99 M USD
Jan 1, 2024
10.99 M USD
-62.07 M USD
-57.53 M USD
Jan 1, 2025
14.20 M USD
-48.13 M USD
-49.59 M USD
Jan 1, 2026 (e)
15.91 M USD
-9.76 M USD
-77.71 M USD
Jan 1, 2027 (e)
15.23 M USD
-9.34 M USD
-52.28 M USD
Jan 1, 2028 (e)
47.46 M USD
-29.11 M USD
-24.38 M USD
Jan 1, 2029 (e)
149.72 M USD
-91.83 M USD
62,684.64 USD
Jan 1, 2030 (e)
313.67 M USD
-192.38 M USD
64.55 M USD

Opus Genetics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 1, 2026, 11:37 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
–––––––39.0019.0010.0014.0015.0015.0047.00149.00313.00
––––––––-51.28-47.3740.007.14–213.33217.02110.07
–––––––100.00100.00100.00100.00100.00100.00100.00100.00100.00
14.0014.0014.0014.0014.0014.0014.0039.0019.0010.0014.0015.0015.0047.00149.00313.00
-18.00-16.00-17.00-20.00-4.00-17.00-56.0018.00-9.00-62.00-48.00-9.00-9.00-29.00-91.00-192.00
–––––––46.15-47.37-620.00-342.86-60.00-60.00-61.70-61.07-61.34
-14.00-9.00-25.00-14.00-6.00-24.00-56.0017.00-9.00-57.00-49.00-77.00-52.00-24.00–64.00
-22.22-35.71177.78-44.00-57.14300.00133.33-130.36-152.94533.33-14.0457.14-32.47-53.85––
0.380.450.570.693.007.7917.8521.4822.0031.57622.22622.22622.22622.22622.22622.22
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Opus Genetics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Opus Genetics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Opus Genetics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Opus Genetics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Opus Genetics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Opus Genetics stock margins

The Opus Genetics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Opus Genetics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Opus Genetics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
100.00 %
-9,624.96 %
-9,625.30 %
Jan 1, 2022
100.00 %
45.74 %
44.89 %
Jan 1, 2023
100.00 %
-52.36 %
-52.42 %
Jan 1, 2024
100.00 %
-564.72 %
-523.40 %
Jan 1, 2025
100.00 %
-339.00 %
-349.33 %
Jan 1, 2026 (e)
100.00 %
-61.33 %
-488.53 %
Jan 1, 2027 (e)
100.00 %
-61.33 %
-343.20 %
Jan 1, 2028 (e)
100.00 %
-61.33 %
-51.38 %

Opus Genetics Stock Revenue, EBIT, Earnings per Share

The Opus Genetics earnings per share therefore indicates how much revenue Opus Genetics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.03 USD
-3.18 USD
-3.18 USD
Jan 1, 2022
1.86 USD
0.85 USD
0.83 USD
Jan 1, 2023
0.87 USD
-0.45 USD
-0.45 USD
Jan 1, 2024
0.35 USD
-1.97 USD
-1.82 USD
Jan 1, 2025
0.02 USD
-0.08 USD
-0.08 USD
Jan 1, 2026 (e)
0.23 USD
-0.02 USD
-1.13 USD
Jan 1, 2027 (e)
0.22 USD
-0.02 USD
-0.76 USD
Jan 1, 2028 (e)
0.69 USD
-0.05 USD
-0.35 USD

Opus Genetics business model & stock analysis

Opus Genetics Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Opus Genetics Employees
Details
Date
Opus Genetics Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Opus Genetics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Opus Genetics historical P/E ratio, EBIT multiple, and P/S ratio

Opus Genetics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Opus Genetics shares outstanding

The number of shares of Opus Genetics was 622.22 M in 2025. This indicates how many shares Opus Genetics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
17.85 M Stocks
Jan 1, 2022
21.48 M Stocks
Jan 1, 2023
22.00 M Stocks
Jan 1, 2024
31.57 M Stocks
Jan 1, 2025
622.22 M Stocks
Jan 1, 2026 (e)
622.22 M Stocks
Jan 1, 2027 (e)
622.22 M Stocks
Jan 1, 2028 (e)
622.22 M Stocks

Opus Genetics stock splits

In Opus Genetics's history, there have been no stock splits.

Current Opus Genetics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
93.33 % (14)
Hold
6.67 % (1)
Sell
0.00 % (0)
12M Price Target
8.16
Last Price
3.71
Currency
USD
12M Return Potential
119.95 %
LTM Return
0 %

Opus Genetics Analyst Rating Actions

DateFirmActionRating
7/6/2026
Chardan Capital
Chardan Capital
MaintainedBuy
7/6/2026
BTIG
BTIG
MaintainedBuy
6/18/2026
Chardan Capital
Chardan Capital
MaintainedBuy
6/17/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
6/16/2026
BTIG
BTIG
MaintainedBuy
6/15/2026
Citizens
Citizens
MaintainedMarket Outperform
5/13/2026
Citizens
Citizens
MaintainedMarket Outperform
3/12/2026
Wedbush
Wedbush
MaintainedOutperform
3/12/2026
Chardan Capital
Chardan Capital
MaintainedBuy
3/2/2026
BTIG
BTIG
MaintainedBuy

Opus Genetics Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
8/11/2026-0.16USD2.49 MUSD2026 Q2
5/13/2026-0.14USD2.96 MUSD2026 Q1
3/30/2026-0.12USD3.37 MUSD2025 Q4
8/11/2025-0.21USD4.08 MUSD2025 Q2

Opus Genetics shareholder structure

% Name
6.27175%
Perceptive Advisors LLC
Perceptive Advisors LLC
5.34140%
Bios Equity Partners, LP.
Bios Equity Partners, LP.
4.85198%
Nantahala Capital Management, LLC
Nantahala Capital Management, LLC
2.62533%
Gallagher (Cam S)
Gallagher (Cam S)
1.76914%
Opaleye Management Inc.
Opaleye Management Inc.
1.73668%
Mink Brook Asset Management LLC
Mink Brook Asset Management LLC

Opus Genetics Beneficial Ownership Filings (SEC 13D/G)

Free Float
42.4%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
9.99%
Perceptive Advisors LLC
Perceptive Advisors LLC
SEC ↗
9.99%
Altium Growth GP, LLC
Altium Growth GP, LLC
SEC ↗
8.50%
Caligan Partners LP
Caligan Partners LP
SEC ↗
8.47%
Adage Capital Management, L.P.
Adage Capital Management, L.P.
SEC ↗
8.33%
Ryan M. Lane
Ryan M. Lane
SEC ↗
8.33%
Martin D. Hoe
Martin D. Hoe
SEC ↗
8.33%
Empery Asset Management, LP
Empery Asset Management, LP
SEC ↗
7.58%
Empery Debt Opportunity Fund, LP
Empery Debt Opportunity Fund, LP
SEC ↗
7.24%
Not Applicable
Not Applicable
SEC ↗
7.18%
Balyasny Asset Management L.P.
Balyasny Asset Management L.P.
SEC ↗

Opus Genetics Executives and Management Board

GM

Dr. George Magrath

(39)

Chief Executive Officer, Director · since 2023

Compensation2.67 M USD
RP

Mr. Ronil Patel

Chief Business Officer

Compensation1.10 M USD
RR

Mr. Richard Rodgers

(58)

Independent Director · since 2020

Compensation899,076.00 USD
BH

Mr. Bernhard Hoffmann

(68)

Senior Vice President - Corporate Development and Operations

Compensation789,918.00 USD
CG

Mr. Cam Gallagher

(54)

Independent Chairman of the Board

Compensation174,620.00 USD

Frequently asked questions about Opus Genetics

Analysts currently set an average price target of 7.88 USD for the Opus Genetics stock (median: 8.16 USD), implying +112.4 % versus the latest price. The consensus is based on 15 analyst ratings.

Opus Genetics Analyst Price Targets 2026

All fundamentals and in-depth analysis of Opus Genetics

Our stock analysis for Opus Genetics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Opus Genetics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Opus Genetics Stock
Opus Genetics Revenue→
Opus Genetics Stock
Opus Genetics Net Income→
Opus Genetics Stock
Opus Genetics P/E→
Opus Genetics Stock
Opus Genetics P/S→
Opus Genetics Stock
Opus Genetics EBIT→
Opus Genetics Stock
Opus Genetics Dividend→
Opus Genetics Stock
Opus Genetics Directors Dealings→
Opus Genetics Stock
Opus Genetics Stocks→
Opus Genetics Stock
Opus Genetics Market capitalization→
Opus Genetics Stock
Opus Genetics Debt→
Opus Genetics Stock
Opus Genetics Liabilities→
Opus Genetics Stock
Opus Genetics Equity→
Opus Genetics Stock
Opus Genetics AAQS→
Opus Genetics Stock
Opus Genetics Employees→
Opus Genetics Stock
Opus Genetics ROE→
Opus Genetics Stock
Opus Genetics ROA→
Opus Genetics Stock
Opus Genetics ROCE→
Opus Genetics Stock
Opus Genetics News→
Opus Genetics Stock
Opus Genetics Analyst Price Targets→

Health Stocks

OragenicsOptus Pharmaceutical CoOramed PharmaceuticalsOptomed OyjOraSure TechnologiesOptiscan ImagingOrchestra Biomed HoldingsOptiPharm CoOrchid PharmaOption Care HealthOrexoOptimizeRxAll Stocks A–Z →